Zero Tariffs, Higher Drug Bills as US and UK Reset Pharma Trade

The United States and the United Kingdom struck a sweeping pharmaceuticals trade deal this week that removes all tariffs on medicines, active ingredients, and medical technology, while locking the UK into a sharp increase in drug spending. 

Under the agreement, the NHS will lift its medicines budget by 25% annually for at least the next three years, marking its biggest sustained rise in over two decades. The UK will also raise the net prices it pays for new drugs by the same margin, directly reshaping one of Europe’s most cost-sensitive healthcare markets.

In return, UK-made medicines are shielded from current and future US Section 232 and Section 301 tariffs, eliminating a key trade risk for exporters. A central pillar of the shift is a fundamental overhaul of the UK’s drug valuation model at NICE, where the current cost-effectiveness ceiling sits around £30,000 per quality-adjusted life year, or just under $40,000. That framework has long been criticised by US drugmakers as suppressing global pricing power.

The deal also softens pressure from the UK’s voluntary pricing scheme, which forces firms to rebate a portion of NHS revenues. That rebate cap is set to fall to 15% in 2026, improving margin visibility for multinational manufacturers.

What Does This Mean for Me?

Markets reacted cautiously. Bristol Myers Squibb shares slipped 0.1%, while AstraZeneca fell about 1% and GSK 0.4%. The agreement effectively ties US tariff relief to higher European drug pricing, tightening the link between trade policy, healthcare inflation, and global pharma cash flows.